<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449433</url>
  </required_header>
  <id_info>
    <org_study_id>16911</org_study_id>
    <secondary_id>I8B-MC-ITSL</secondary_id>
    <secondary_id>2017-003459-47</secondary_id>
    <nct_id>NCT03449433</nct_id>
  </id_info>
  <brief_title>A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Mixed Meal Tolerance Test Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LY900014 Compared to Humalog Following a Single Dose in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart
      (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by
      injection under the skin. The study will assess how fast the active ingredient (insulin
      lispro or insulin aspart) gets into the blood stream and how long it takes the body to remove
      it. A test meal will be given to trial participants to assess the course of the blood sugar
      lowering effect of the investigational products. The safety and tolerability of LY900014 will
      also be assessed. Screening is required within 14 days prior to the lead in. For each
      participant, the study will last up to 91 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Plasma Concentration Curve (AUC) for Each Treatment Arm</measure>
    <time_frame>Predose through 420 minutes postdose in each period</time_frame>
    <description>Pharmacokinetics: AUC for Each Treatment Arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Glucose AUC Relative to a Mixed Meal Tolerance Test (MMTT)</measure>
    <time_frame>Predose through 300 minutes postdose in each period</time_frame>
    <description>Change from Baseline in the Glucose AUC Relative to a MMTT</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subcutaneous (SC) dose of LY900014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (Humalog®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin lispro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart (NovoRapid®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin aspart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart (Fiasp®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin aspart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Lispro (Humalog®)</arm_group_label>
    <other_name>Humalog®</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Aspart (NovoRapid®)</arm_group_label>
    <other_name>NovoRapid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Aspart (Fiasp®)</arm_group_label>
    <other_name>Fiasp®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female participants with Type 1 Diabetes Mellitus (T1DM) for at least 1
             year

          -  Have a body mass index (BMI) of 18.5 to 35.0 kilogram per meter square (kg/m²)

          -  Have a glycated hemoglobin (HbA1c) less than (&lt;)9.0 percent (%)

          -  Have had no episodes of severe hypoglycaemia in the last 6 months

        Exclusion Criteria:

        - Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal,
        endocrine (apart from T1DM), hematological, or neurological disorders capable of
        significantly altering the absorption, metabolism or elimination of drugs; of constituting
        a risk when taking the investigational product; or of interfering with the interpretation
        of data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

